Executives Want in, but Researchers Want Out — How Pharma’s US Job Picture Is Changing

Why It Matters

The shift reshapes the competitive landscape, concentrating strategic decision‑making in the U.S. while risking a brain drain that may erode the country’s research pipeline and future drug discovery capacity.

Key Takeaways

• US pharma manufacturing investment exceeds $370 billion by 2030
• Executives relocate to US to stay near corporate “mothership.”
• 75% of US scientists considered leaving; many now have contracts
• European grants for US scientists rose from 60 to 169
• Potential US research talent gap could slow innovation

Pulse Analysis

The surge in U.S. pharmaceutical manufacturing reflects a strategic pivot toward domestic production, driven by robust capital availability, streamlined regulatory pathways, and incentives that outpace European counterparts. Companies view the United States as the "mothership" for innovation, positioning executive talent close to decision‑makers and supply‑chain hubs. This concentration of leadership amplifies the United States' influence over global drug pipelines, but it also intensifies competition for skilled managers who can navigate complex market dynamics.

Concurrently, federal budget constraints and reduced grant programs have eroded the financial foundation for American researchers. Recent data show a sharp rise in U.S. scientists applying for European Research Council grants, with early‑career applications more than doubling between 2024 and 2026. While salaries remain higher in the United States, many researchers accept lower pay abroad in exchange for stable funding and collaborative networks. This migration is not merely speculative; contracts are being signed, signaling a tangible shift in the global research talent pool.

The divergent trajectories pose strategic challenges for the biotech ecosystem. Executives benefit from proximity to capital and rapid regulatory approval, yet a thinning domestic research base could hinder long‑term innovation and drug discovery. Policymakers and industry leaders must balance incentives that retain scientific talent with the continued attraction of manufacturing investment. Failure to address the emerging brain drain may widen the innovation gap, allowing European and Canadian hubs to capture a larger share of breakthrough therapies.